Endostatin EntreMed

IDrugs

Volumn 3, Issue 7, 2000, Pages 799-810

  Grosios, Konstantina ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748337535     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (180)

1. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of netastases by a lewis lung carcinoma. O'Reilly Michael S, Holmgren Lars, Shing Yuen, Chen Catherine, Rosenthal Rosalind, Moses Marsha, Lane William, Cao Yihai, Sage E Helene, Folkman Judah CELL 1994 79 315-328
2. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Holmgren L, O'Reilly MS, Folkman J NAT MED 1995 1 2 149-153
3. Entrmed, Inc. license Endostatin, a newly discovered angiogenesis inhibitor, from Children's Hospital at Harvard. Entremed Inc PRESS RELEASE 1996 December 05
4. Combined anti-angiogenics promising SCRIP 1996 2189 23
5. Malignant tumors in laboratory animals checked by powerful new angiogenesis inhibitor. Children's Hospital of Boston PRESS RELEASE 1997 January 24
6. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BJ, Folkman J CELL 1997 88 January 24 277-285
7. Angiogenesis inhibiton as a drug target for disease: an update. Seed MP EXP OPIN INVEST DRUGS 1996 5 12 1617-1637
8. PF4 shows promise as cancer treatment. DRUG NEWS PERSPECT 1990 3 1 44-45
9. EntreMed licences new breast cancer treatment. SCRIP 1997 2207 13
10. Therapeutic Implications and Mechanisms of Angiogenesis Third International Conference: Novel Therapeutic Development IBC, Boston, MA, USA. Mousa SA IDDB MEETING REPORT 1997 February 10-11
11. Entremed Inc FORM S-1 1996 June 11
12. EntreMed Inc. reports fiscal 1997 first quarter results and receives Small Business Innovative Research Grant from the National Institutes of Health Entremed Inc PRESS RELEASE 1997 May 13
13. American Society of Clinical Oncology, 33rd Annual Meeting (Part VI) Denver, CO, USA Hutchinson E IDDB MEETING REPORT 1997 May 17-20
14. [Well-aimed cancer therapy]. Gezielt den Nachschub abschneiden. Hellwig B DTSCH APOTH ZTG 1997 137 7 30-32
15. EntreMed Inc and the National Cancer Institute sign letters of intent to develop antiangiogenic drug therapies. Entremed Inc PRESS RELEASE 1997 August 07
16. Hitting cancer where it hurts. Sunassee K, Vile R CURR BIOL 1997 7 5 R282-R285
17. Angiogenesis: A dynamic balance of stimulators and inhibitors. Iruela Arispe ML, Dvorak HF THROMB HAEMOST 1997 78 1 672-677
18. Hepatocytes synthesize the precursor of the angiogenesis inhibitor endostatin. Cramer T, Bauer M, Herbst H, Bechstein WO, Neuhaus P, Riecken EO, Schuppan D GASTROENTEROLOGY 1997 112 4 Suppl A1249
19. Angiogenesis Targets - Inhibitors and Inducers. IBC's Fourth International Conference, San Francisco, CA, USA. Robinson GS IDDB MEETING REPORT 1997 July 24-27
20. Angiostatin induces and sustains dormancy of human primary tumors in mice. O'Reilly MS, Holmgren L, Chen CC, Folkman J NAT MED 1996 2 689-692
21. Growth factor antagonists for the treatment of diabetic vascular complications. Tilton RG, Dixon RAF, Brock TA EXP OPIN INVEST DRUGS 1997 6 11 1671-1684
22. Angiogenesis and its inhibitors. Ono M, Kuwano M JPN J CANCER CHEMOTHER 1997 24 11 1585-1593
23. Entremed Inc announces publication of positive preclinical findings using endostatin protein therapy in experimental cancer. Entremed Inc PRESS RELEASE 1997 November 28
24. Connective Tissue Oncology Society, Third Annual Scientific Meeting. Hotel Principe di Savoia, Milan, Italy Verrill M IDDB MEETING REPORT 1937 November 6-8
25. Angiogenesis: the unifying concept in cancer? [news]. Saphir A J NATL CANCER INST 1997 89 22 1658-1659
26. A cancer therapy resistant to resistance [news; comment]. Kerbel RS NATURE 1997 390 6658 335-336
27. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Boehm T, Folkman J, Browder T, O'Reilly MS NATURE 1997 390 6658 404-407
28. Isolation and characterization of the circulating form of human endostatin. Standker L, Schrader M, Kanse SM, Juergens M, Forssmann WG, Preissner KT FEBS LETT 1997 420 2-3 129-133
29. Isolation and characterization of the circulating form of human endostatin. Standker L, Schrader M, Kanse SM, Jurgens M, Forssmann WG, Preissner KT FEBS LETT 1997 420 2-3 129-133
30. A flanking attack on cancer [news]. Hanahan D NAT MED 1998 4 1 13-14
31. Tumor regression after endostatin therapy [letter]. Black WR, Agner RC NATURE 1998 391 6666 450
32. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Saarela J, Ylikarppa R, Rehn M, Purmonen S, Pihlajaniemi T MATRIX BIOL 1998 16 6 319-328
33. Genetic strategies for anti-angiogenic therapy of solid tumors. Nguyen J, Wu P, Hlatky L, Terwilliger EF CANCER GENE THER 1997 46 Suppl. S41
34. EntreMed Inc reports fiscal 1997 year-end results. Entremed Inc PRESS RELEASE 1998 March 31
35. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolution. Hohenester E, Sasaki T, Olsen BR, Timpl R EMBO J 1998 17 6 1656-1664
36. Tumour regression after endostatin therapy [5]. Black WR, Agner RC NATURE 1998 391 6666 450
37. [Successful animal experiment with the angiogenesis inhibitor endostatin for tumor therapy]. Tumortherapie: Angiogenese-Hemmstoff Endostatin im Tierexperiment Erfolgreich. Wasielewski S DTSCH APOTH ZTG 1998 138 9 27-28
38. EntreMed Inc issues statement regarding angiostatin protein and endostatin protein. Entremed Inc PRESS RELEASE 1998 May 4
39. EntreMed stock jumps on cancer drug reports. BIOWORLD WEEK 1998 6 19 3
40. EntreMed urges caution as stock soars on cancer "cure". SCRIP 1998 2332/3 19
41. Entremed Inc reports fiscal 1998 first quarter results. Entremed Inc PRESS RELEASE 1998 May 15
42. Crystal structure of EntreMed Inc's Endostatin protein revealed/company signs sponsored research agreement with leading harvard scientist. Entremed Inc PRESS RELEASE 1998 June 1
43. Bone marrow engraftment of murine hematopoietic cells transduced with retroviral vectors expressing the angiogenesis inhibitors angiostatin and endostatin. Pawliuk R, Bachelot T, Boehm T, Folkman J, Leboulch P PROC AM ASSOC CANCER RES 1998 39 0 555
44. EntreMed Inc presents at Bio '98 Investor & Partnering conference Entremed Inc PRESS RELEASE 1998 June 15
45. American Association for Cancer Research 1998: promises and prospects for the next century. Lavelle F EXP OPIN INVEST DRUGS 1998 7 6 1015-1021
46. Mechanisms of angiogenesis in vascular disorders: Potential therapeutic targets. Mousa SA DRUGS FUTURE 1998 23 1 51-60
47. Annual Report 1997 - EntreMed. EntreMed Inc ANNUAL REPORT 1997 December 31
48. NCI-EORTC 10th Symposium (Part II) New Drugs in Cancer Therapy - Amsterdam, The Netherlands. Niculescu Duvaz I IDDB MEETING REPORT 1998 June 16-19
49. EntreMed Inc reports fiscal 1998 second quarter results Endostatin™ protein well tolerated in monkeys. Entremed Inc PRESS RELEASE 1998 August 10
50. Are angiostatin and endostatin cures for cancer? Harris AL LANCET 1998 351 9116 1598-1599
51. [Tumor angiogenesis inhibitors, or the medias and science]. Inhibiteur de l'angiogenese tumorale: Aspect mediatique et aspect pratique. Raymond E PRESSE MED 1998 27 24 1221-1224
52. [Angiogenesis inhibitors as wonder drug against cancer?] Angiogeneseinhibitoren: 'Wundermittel' gegen Krebs? Oo WC, Baumgartner M DTSCH APOTH ZTG 1998 138 20 48-49
53. Metastasis Research Society VII International Congress (Part I). San Diego, CA, USA. van Noorden CJF IDDB MEETING REPORT 1998 October 7-10
54. EntreMed Inc reports fiscal 1998 third quarter results. Entremed Inc PRESS RELEASE 1998 October 27
55. Starving tumors of their lifeblood [news]. Ezzell C SCI AM 1998 279 4 33-34
56. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R EMBO J 1993 17 15 4249-4256
57. Inhibitors of angiogenesis enter phase III testing [news]. Nelson NJ J NATL CANCER INST 1993 90 13 960-963
58. Therapy for non-small cell lung cancer: new concepts based on molecular biology. Tanaka F, Wada H, Hitomi S NIPPON GEKA GAKKAI ZASSHI 1998 99 5 285-290
59. Shouting 'cure!' - or whispering 'hope' - in a crowded cancer ward [editorial]. Healy BP J WOMENS HEALTH 1998 7 5 489-490
60. [Anti-angiogenetic therapy of tumors in the animal experiment]. Antiangiogenetische Therapie von Tumoren im Tierexperiment Anonymous STRAHLENTHER ONKOL 1998 174 6336-338
61. Cancer experts offer healthy dose of skepticism toward hype over antiangiogenesis agents [news]. Phillips P J AM MED ASSOC 1998 279 24 1936-1937
62. Cancer "breakthrough" is still in the future. Anonymous HEALTH NEWS 1998 4 7 6
63. The power of the front page of The New York Times [news]. Marshall E SCIENCE 1998 280 5366 996-997
64. Cancer 'cure' article stirs up hot debate [news] [see comments]. Wadman M NATURE 1998 393 6681 104-105
65. Angiogenesis and tumor metastasis. Zetter BR ANNU REV MED 1998 49 4
66. Hepatocytes as a source of collagen type XVIII endostatin. Schuppan D, Cramer T, Bauer M, Strefeld T, Hahn EG, Herbst H LANCET 1998 352 9131 879-880
67. Zinc-dependent dimers observed in crystals of human endostatin. Ding YH, Javaherian K, Lo KM, Chopra R, Boehm T, Lanciotti J, Harris BA, Li Y, Shapiro R, Hohenester E, Timpl R, Folkman J, Wiley DC PROC NATL ACAD SCI U S A 1998 95 18 10443-10448
68. Two sides of the same coin: Stop angiogenesis for cancer and encourage it for coronary artery disease. Sorelle R CIRCULATION 1998 98 5 383-384
69. Antiangiogenic tumour therapy: Will it work? Augustin HG TRENDS PHARMACOL SCI 1998 19 6 216-222
70. Cancer Rx duo offers promise with caution. Portyansky E DRUG TOPICS 1998 142 10 21).
71. 4-Anilinoquinazoline derivatives. EXP OPIN THER PAT 1998 8 4 475-478
72. [Successful animal experiment with the angiogenesis inhibitor endostatin for tumor therapy]. Tumortherapie: Angiogenese-Hemmstoff Endostatin im Tierexperiment Erfolgreich. Wasielewski S DTSCH APOTH ZTG 1998 138 9 27-28
73. Tumour regression after endostatin therapy [5]. Black WR, Agner RC NATURE 1998 391 6666 450
74. A new approach to fighting cancer? Sato TN PROC NATL ACAD SCI U S A 1998 95 11 5843-5844
75. Expression pattern of collagen XVIII in HCC. Cramer T, Bauer M, Herbst H, Riecken EO, Schuppan D J HEPATOL 1998 28 SUPPL. 1 90
76. Predictive Oncology and Therapy - Fourth International Symposium (Part II). Nice, France. Leoni F IDDB MEETING REPORT 1998 October 24-27
77. EntreMed Inc issues statement responding to Wall Street Journal article. Entremed Inc PRESS RELEASE 1998 November 12
78. Drug development pipeline. DRUG DEV PIPELINE 1998 3 12 1-4
79. Entremed Inc reports fiscal 1998 year-end financial results. Entremed Inc PRESS RELEASE 1999 March 01
80. Copper chelators promoted as angiogenesis inhibitors; Cell Therapeutics takes license. EMERGING PHARMACEUTICALS 1999 8 1 5
81. EntreMed shares rebound on good news. BIOWORLD WEEK 1999 7 7 4
82. Angiogenesis: Therapeutic Applications, Bethesda, MD, USA. Williams J IDDB MEETING REPORT 1999 February 22-23
83. EntreMed Inc signs cooperative research and development agreement "CRADA" with the National Cancer Institute to advance studies of an orally active antitumor and antiangiogenic agent 2-methoxyestradiol. Entremed Inc PRESS RELEASE 1999 April 6
84. EntreMed scientists report potent antiangiogenic effects in preclinical studies of recombinant human endostatin and angiostatin protein at the American Association for Cancer Research Annual Meeting - recombinant human endostatin manufacturing process validated for the production of material for human trials. Entremed Inc PRESS RELEASE 1999 April 14
85. American Association for Cancer Research - 90th Annual Meeting (Part IX). Philadelphia, PA, USA. Melnicoff MJ IDDB MEETING REPORT 1999 April 10-14
86. American Association for Cancer Research - 90th Annual Meeting (Part X). Philadelphia, PA, USA. Boven E IDDB MEETING REPORT 1999 April 10-14
87. Thalomid oncology is proof of antiangiogenic drug concept - EntreMed. FDC REPORTS PINK SHEET 1999 61 15 5
88. Pharmacokinetics and range-finding toxicity studies of recombinant human Endostatin in cynomolgus monkeys. Tomaszewski JE, Schweikart KM, Covey JM, Turner N, Tosca PJ, Hassler C, Simpson B, Fogler WE, Sim BKL PROC AM ASSOC CANCER RES 1999 40 ABS 2553
89. Mouse pharmacokinetics and pharmacological basis for drug development of recombinant human Endostatin. Tomaszewski JE, Schweikart KM, Covey JM, Turner N, Tosca PJ, Simpson B, Fogler WE, Sim BKL PROC AM ASSOC CANCER RES 1999 40 ABS 2554
90. Endostatin-induced inhibition of endothelial cell migration correlates with in vivo anti-tumor activity. Fortier AH, Nelson B, Vu H, Plum S, Fogler WE, Sim BKL PROC AM ASSOC CANCER RES 1999 40 ABS 2745
91. American Thoracic Society/American Lung Association 1999 International Conference (Part II), San Diego, CA, USA. Jedlicka A IDDB MEETING REPORT 1999 April 23-28
92. EntreMed Inc announces phase I human clinical trial sites for recombinant human endostatin protein sites named at 35th annual meeting of American Society of Clinical Oncologists. Entremed Inc PRESS RELEASE 1999 May 17
93. American Society of Clinical Oncology - 35th Annual Meeting (Part III) Atlanta, GA, USA. McKinnon C IDDB MEETING REPORT 1999 May 15-18
94. Systemic approaches for prostate cancer. Eisenberger MA ASCO EDUC BOOK 1999 35 May 15-18 484-491
95. New systemic approaches for prostate cancer treatment. Isaacs JT ASCO EDUC BOOK 1999 35 May 15-18 492-493
96. Potent inhibition of experimental metastases and primary tumors by recombinant human Endostatin that is suitable for human use. Sim BKL, Fogler WE, Zhou XH, Liang H, Madsen JW, O'Reilly MS, Panigrahy D, Fortier AH PROC AM ASSOC CANCER RES 1999 40 Abs 4092
97. EntreMed Inc announces licensing agreement with Calbiochem-Novabiochem Corp for the sale of research grade endostatin protein and angiostatin protein. EntreMed Inc PRESS RELEASE 1999 June 24
98. EntreMed Inc announces extension of sponsored research agreement with Folkman Lab at Children's Hospital, Boston. EntreMed Inc PRESS RELEASE 1999 June 30
99. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Folkman J NAT MED 1995 1 1 27-31
100. EntreMed Inc announces FDA has granted permission for Endostatin protein clinical trials to begin. EntreMed Inc PRESS RELEASE 1999 July 27
101. EntreMed Inc reports fiscal 1999 second quarter results executives increase share ownership in recent private placement. EntreMed Inc PRESS RELEASE 1999 August 11
102. Cell Genesys and EntreMed announce research collaboration for cancer gene therapy. Cell Genesys Inc PRESS RELEASE 1999 August 17
103. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D SCIENCE 1999 284 5415 808-812
104. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Nguyen JT, Wu P, Clouse ME, Hlatky L, Terwilliger EF CANCER RES 1998 58 5673-5677
105. EntreMed Inc announces commencement of patient enrollment for phase I clincal trials of Endostatin protein. EntreMed Inc PRESS RELEASE 1999 September 28
106. Colloidal Gold as a targeted drug/gene delivery system. Cytimmune Sciences Inc PRESS RELEASE 1999 October 07
107. Molecular aspects of metastasis - AACR Special Conference in Cancer Research, Snowmass, CA, USA. Miele ME IDDB MEETING REPORT 1999 September 22-26
108. Genzyme Molecular Oncology to secure cash and cancer programs to advance its cancer product pipeline. Genzyme Molecular Oncology PRESS RELEASE 1999 October 18
109. EntreMed science highlighted at the Biological Therapy of Cancer Meeting in Boston. EntreMed Inc PRESS RELEASE 1999 October 28
110. Congress Of Neurological Surgeons 49th Annual Meeting Boston, MA, USA. Rutka JT IDDB MEETING REPORT 1999 October 30 - November 4
111. Binding site for Endostatin protein identified. EntreMed Inc PRESS RELEASE 1999 November 19
112. Mechanisms of tumor angiogenesis and therapeutic implications: Angiogenesis inhibitors. Malonne H, Langer I, Kiss R, Atassi G CLIN EXP METASTASIS 1999 17 1 1-14
113. EntreMed Inc signs letter of understanding with Chiron Corp for the production of bulk Endostatin protein for phase II clinical trials. EntreMed Inc PRESS RELEASE 1999 December 13
114. Bone marrow angiogenesis, angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Bertolini F, Mancuso P, Paolucci M, Corsini C, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Scalamogna R, Martinelli G BLOOD 1999 94 10 4286
115. Aeterna Neovastat will be 12th antiangiogenesis drug to reach phase III. FDC REPORTS PINK SHEET 2000 62 9 22-23
116. Review of AACR Meeting: New Research Approaches in the Prevention and Cure of Prostate Cancer, 2-6 December 1998, Indian Wells, CA. Ornstein DK, Dahut WL, Liotta LA, Emmert BUCKMR BIOCHIM BIOPHYS ACTA REV CANCER 1994 1424 1 11-19
117. Tumor angiogenesis: Biology and therapeutic prospects. Harris SR, Thorgeirsson UP IN VIVO 1998 12 6 563-570
118. Potent inhibition of experimental metastases and primary tumors by recombinant human Endostatin that is suitable for human use. Sim BKL, Fogler WE, Zhou XH, Liang H, Madsen JW, O'Reilly MS, Panigrahy D, Fortier AH PROC AM ASSOC CANCER RES 1999 40 620-621
119. Endostatin™-induced inhibition of endothelial cell migration correlates with in vivo anti-tumor activity. Fortier AH, Nelson B, Vu H, Plum S, Fogler WE, Sim BKL PROC AM ASSOC CANCER RES 1999 40 415
120. Potentiation of antitumor effects of angiostatin and endostatin by immunostimulation. Li M, Zhu Z, Huang X, Zhao Q, Wong M, Gorelik E PROC AM ASSOC CANCER RES 2000 41 April 1-5 Abs 3094
121. EntreMed Inc reports fiscal 1999 year-end financial results. EntreMed Inc PRESS RELEASE 2000 March 22
122. Overexpression of trigger factor prevents aggregation of recombinant proteins in Escherichia coli. Nishihara K, Kanemori M, Yanagi H, Yura T APPL ENVIRON MICROBIOL 2000 66 3 884-889
123. Preview of the American Association for Cancer Research 91st Annual Meeting, San Francisco, CA, USA. Brown H, Worker C IDDB MEETING REPORT 2000 April 1-5
124. Targets and Molecules: The Science of Drug Discovery, Cold Spring Harbor, NY, USA. Fernandes PB IDDB MEETING REPORT 2000 March 8-10
125. EntreMed research emphasizing low-dose cancer therapy featured at Annual Meeting of American Association for Cancer Research. EntreMed Inc PRESS RELEASE 2000 April 04
126. EntreMed scientists reveal anticancer mechanisms for endostatin and 2-methoxyestradiol at the Annual Meeting of American Association for Cancer Research - Next-generation products also highlighted at meeting. EntreMed Inc PRESS RELEASE 2000 April 05
127. Endostatin stimulates TPA mediated plasmin formation. Reijerkerk A, Mosnier LO, Bouma BN, Meijers JC, Voest EE, Gebbink MF PROC AM ASSOC CANCER RES 2000 41 April 1-5 Abs 3111
128. Genetic modification of human endostatin: RGD-motif potentiates anti-tumor activity. Yokoyama Y, Ramakrishnan S PROC AM ASSOC CANCER RES 2000 41 April 1-5 Abs 3112
129. Increased response to induced angiogenesis in aortic explants from collagen VIII/endostatin knockout mice. Li Q, Fukai N, Felbor U, Tamarkin L, Oh SP, Olsen BR PROC AM ASSOC CANCER RES 2000 41 April 1-5 Abs 3113
130. Tropomyosin identified as a potential modulator of the anti-angiogenic activity of Endostatin protein. MacDonald NJ, Shivers WY, Plum S, Sim BKL PROC AM ASSOC CANCER RES 2000 41 April 1-5 Abs 3118
131. American Association of Cancer Research 91st Annual Meeting (Part XIX). Interview with Dr James M Pluda, Senior Clinical Investigator, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA, San Francisco, CA, USA. Worker C IDDB MEETING REPORT 2000 April 1-5
132. EntreMed Inc commences large-scale production of endostatin protein for additional clinical trials GMP manufacturing now underway at Chiron Corporation. EntreMed Inc PRESS RELEASE 2000 April 25
133. Experimental Biology 2000 Recent Progress in Cancer Biology and Therapy, San Diego, CA, USA. Hu E IDDB MEETING REPORT 2000 April 15-18
134. Summary of the American Association for Cancer Research 91st Annual Meeting San Francisco, CA, USA. Worker C, Brown H IDDB MEETING REPORT 2000 April 1-5
135. Entremed Inc responds to premature public disclosure of patient data from endostatin trial. EntreMed Inc PRESS RELEASE 2000 May 12
136. The Miami Winter Symposium 2000 - DNA, RNA and Cancer Miami, FL, USA. Salmons B IDDB MEETING REPORT 2000 February 5-9
137. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Blezinger P, wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W NATURE BIOTECHNOL 1999 17 343-348
138. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D SCIENCE 1999 284 808-812
139. Disruption of the KEX1 gene in Pichia pastoris allows expression of full-length murine and human endostatin. Boehm T, Pirie-Shepherd S, Trinh LB, Shiloach J, Folkman J YEAST 1999 15 563-572
140. Zinc-binding of endostatin is essential for its antiangiogenic activity. Boehm T, O'Reilly MS, Keough K, Shiloach J, Shapiro R, Folkman J BIOCHEM BIOPHYS RES COMMUN 1998 252 190-194
141. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Chang Z, Choon A, Friedl A, AM J PATHOL 1999 155 71-76
142. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Chen QR, Kumar D, Stass SA, Mixson AJ CANCER RES 1999 59 3308-3312
143. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G NEW ENGL J MED 1991 325 164-170
144. Behind the headlines of endostatin's ups and downs. Cohen J SCIENCE 1999 283 1250-1251
145. Endostatin induces endothelial cell apoptosis. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Sukhatme VP J BIOL CHEM 1999 274 11721-11726
146. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M, Sukhatme VP CANCER RES 1999 59 189-197
147. Cloning, expression, and in vitro activity of human endostatin. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP BIOCHEM BIOPHYS RES COMMUN 1999 258 345-352
148. Correlation between serum endostatin and vascular endothelial growth factor (VEGF) levels in patients with renal cancer. Feldman AL, Linehan WM, Yang JC, Alexander HR, Tamarkin L, Paciotti GF, Libutti SK PROC AM ASSOC CANCER RES 2000 41 272(ABS734)
149. Tumor angiogenesis and tissue factor. Folkman J NAT MED 1996 2 13-14
150. Serum concentrations of endostatin in patients with vulvar cancer. Hefler L, Tempfer C, Kainz C, Obermair A GYNECOL ONCOL 1999 74 151-152
151. Variable zinc coordination in endostatin. Hohenester E, Sasaki T, Mann K, Timpl R J MOL BIOL 2000 297 1-6
152. Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy. Indraccolo S, Minuzzo S, Gola E, Habeler W, Carrozzino F, Noonan D, Albini A, Santi L, Amadori A, Chieco-Bianchi L INT J BIOL MARKERS 1999 14 251-256
153. Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV. John H, Preissner KT, Forssmann WG, Standker L BIOCHEMISTRY 1999 38 10217-10224
154. Continuous endostatin release using alginate-polylysine polymer encapsulated producer cells. Joki T, Hesse O, Zhang J, Zhu J, Abe T, Machlouf M, Carroll RS, McLBlack P PROC AM ASSOC CANCER RES 2000 41 524(Abs3342)
155. Anticancer drug targets: approaching angiogenesis. Keshet E, Ben-Sasson SA J CLIN INVEST 1999 104 1497-1501
156. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Figg WD, Allegra C BIOCHEM BIOPHYS RES COMMUN 2000 268 183-191
157. Increased response to induced angiogenesis in aortic explants from collagen XVII/endostatin knock-out mice. Li Q, Fukai N, Felbor U, Tamarkin L, Oh SP, Li E, Olsen BR PROC AM ASSOC CANCER RES 2000 41 488 (Abs3113)
158. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls. Miosge N, Sasaki T, Timpl R FASEB J1999 13 1743-1750
159. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J CIRCULATION 1999 13 1726-1732
160. Mouse Col18a1 is expressed in tissue specific manner as three alternative variants and is localised in basement membrane zones. Muragaki Y, Timmons S, Griffith CM, Oh SP, Fadel B, Quertermous T, Olsen BR PROC NATL ACAD SCI U S A 1995 92 8763-8767
161. Collagen XVIII is localised in sinusoids and basement membrane zones and expressed by hepatocytes and activated stellate cells in fibrotic human liver. Musso O, Rehn M, Saarela J, Theret N, Lietard J, Hintikka E, Lotrian D HEPATOLOGY 1998 28 98-107
162. Two C-terminal peptides of the endostatin precursor collagen XVIII are reciprocally regulated in association with tumour angiogenesis in human hepatocellular carcinomas. Musso O, Theret N, Rehn M, Hejasvaara R, Pihlajaniemi T, Clement B PROC AM ASSOC CANCER RES 2000 41 167 Abs1 067
163. The chick embryo aortic arch assay: A new, rapid, quantifiable in vitro method for testing the efficacy of angiogenic and anti-angiogenic factors in a three-dimensional, serum-free organ culture system. Muthukkaruppan V, Shinnere BL, Lewis RL, Park SY, Baechler B, Auerbach R PROC AM ASSOC CANCER RES 2000 41 65 Abs 415
164. Isolation and sequencing of cDNAs for proteins with multiple damains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Oh SK, Kamagata Y, Muragaki Y, Timmons S, Ooshima A, Olsen BR PROC NATL ACAD SCI U S A 1994 91 4229-4233
165. Characterisation of the mouse gene for the alpha chain of type XVIII collagen (Col18a1) reveals that the three variant N-terminal polypeptide forms are transcribed from two widely separated promoters. Rehn M, Hintikka E, Pihlajaniemi T GENOMICS 1996 32 436-446
166. Alpha 1 (XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Rehn M, Pihlajaniemi T PROC NATL ACAD SCI U S A 1994 91 4234-4238
167. Endostatin stimulates TPA mediated plasmin formation. Reijerkerk A, Monsier LO, Bouma BN, Meijers JC, Voest EE, Gebbink MF PROC AM ASSOC CANCER RES 2000 41 488 Abs 3111
168. What is all the hullabaloo about endostatin? Rowe PM LANCET 1999 353 732
169. Reality testing in cancer treatment: the phase I trial of endostatin. Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch Jr TJ ONCOLOGIST 1999 4 501-508
170. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in the basement membrane zones in humans. Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T AM J PATHOL 1998 153 611-626
171. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U, Hohenester E, Timpl R EMBO J 1999 18 6240-6248
172. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Taddei L, Chiarugi P, Brogelli L, Cirri P, Magnelli L, Raugei G, Ziche M BIOCHEM BIOPHYS RES COMMUN 1999 263 340-345
173. Anticancer activity of endostatin redeemed. Wadman M NATURE 1999 397 549
174. The generation of endostatin is mediated by elastase. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J CANCER RES 1999 59 6052-6056
175. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR EMBO J 1999 18 4414-4423
176. Genetic modification of human endostatin: RGD-motif potentiates anti-tumor activity. Yokoyama Y, Ramakrishnan S PROC AM ASSOC CANCER RES 2000 41 488 Abs 3112
177. Mouse endostatin inhibits the formation of lung and liver metastases Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, Tanabe KK CANCER RES 1999 59 6251-6256
178. American Society of Clinical Oncology 36th Annual Meeting (Part VIII) Media Sessions and Integrated Symposium, New Orleans, LA, USA. Muhsin M IDDB MEETING REPORT 2000 May 20-23
179. Purification and characterization of recombinant murine endostatin in E. coli. You WK, So SH, Lee H, Park SY, Yoon MR, Chang SI, Kim HK, Joe YA, Hong YK EXP MOL PATHOL 1999 31 197-202
180. EntreMed, Inc. First Security Van Kasper ANALYST REPORT 1999 April 21